Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

IKT | Inhibikase Therapeutics Inc

Index	-	P/E	-	EPS (ttm)	-4.17	Insider Own	22.48%	Shs Outstand	4.20M	Perf Week	11.20%
Market Cap	7.44M	Forward P/E	-	EPS next Y	-3.43	Insider Trans	0.00%	Shs Float	4.15M	Perf Month	-33.01%
Income	-19.03M	PEG	-	EPS next Q	-1.20	Inst Own	18.52%	Short Float / Ratio	0.55% / 0.45	Perf Quarter	-61.50%
Sales	0.25M	P/S	29.75	EPS this Y	23.61%	Inst Trans	-23.72%	Short Interest	0.02M	Perf Half Y	-65.91%
Book/sh	3.68	P/B	0.38	EPS next Y	-3.94%	ROA	-67.55%	Target Price	27.00	Perf Year	-74.26%
Cash/sh	3.91	P/C	0.36	EPS next 5Y	-	ROE	-77.72%	52W Range	0.95 - 6.94	Perf YTD	-53.67%
Dividend	-	P/FCF	-	EPS past 5Y	-76.13%	ROI	-97.02%	52W High	-79.98%	Beta	0.89
Dividend %	-	Quick Ratio	8.04	Sales past 5Y	46.79%	Gross Margin	32.10%	52W Low	46.24%	ATR	0.21
Employees	6	Current Ratio	8.04	Sales Q/Q	1676.71%	Oper. Margin	-7850.03%	RSI (14)	37.60	Volatility	9.62% 14.45%
Optionable	No	Debt/Eq	0.02	EPS Q/Q	-0.18%	Profit Margin	-7557.69%	Rel Volume	0.68	Prev Close	1.44
Shortable	Yes	LT Debt/Eq	0.01	Earnings	Aug 14 AMC	Payout	-	Avg Volume	50.78K	Price	1.39
Recom	2.00	SMA20	-17.11%	SMA50	-33.74%	SMA200	-58.62%	Volume	34,349	Change	-3.47%

Sep-20-23 08:30AM	Inhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading Activity (GlobeNewswire) +17.82%
Aug-24-23 08:30AM	Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib (PR Newswire)
Aug-22-23 08:05AM	Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders (PR Newswire) -10.33%
Aug-21-23 08:30AM	Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib (PR Newswire)
Aug-17-23 08:30AM	Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro (PR Newswire)
11:47PM	Loading…
Aug-15-23 11:47PM	Q2 2023 Inhibikase Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -6.02%
Aug-14-23 04:20PM	Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity (PR Newswire)
Aug-07-23 08:05AM	Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023 (PR Newswire)
Jul-17-23 04:05PM	Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements (PR Newswire)
Jun-29-23 09:29AM	Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split (PR Newswire)
Jun-22-23 08:05AM	Inhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study (PR Newswire) +9.64%
Jun-21-23 08:05AM	Inhibikase Therapeutics Initiates Medical and Patient Awareness Campaign for its Phase 2 '201' Trial Evaluating IkT-148009 in Parkinson's Disease (PR Newswire)
May-30-23 08:05AM	Inhibikase Therapeutics to Present at the LD Micro Invitational XIII (PR Newswire)
May-24-23 12:04PM	Inhibikase Therapeutics: A Novel And Promising Approach To Neurodegeneration And Oncology (News Direct)
May-17-23 06:11AM	Inhibikase Therapeutics First Quarter 2023 Earnings: US$0.16 loss per share (vs US$0.18 loss in 1Q 2022) (Simply Wall St.)
07:45AM	Loading…
May-16-23 07:45AM	Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2 '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease (PR Newswire)
May-15-23 08:30AM	Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity (PR Newswire) +7.72%
May-09-23 07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
May-08-23 08:05AM	Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023 (PR Newswire)
May-04-23 08:05AM	Inhibikase Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference (PR Newswire) +6.62%
May-02-23 03:30PM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
Apr-26-23 08:00AM	Inhibikase Therapeutics Provides Safety and Functional Update on its Phase 1/1b 101 Trial and its Phase 2 IkT-148009 201 Trial in Parkinson's Disease (PR Newswire) -7.90%
Apr-24-23 09:00AM	Keynotes, Educational Panels and 77 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 25-27, 2023 at the Horseshoe Hotel & Casino in Las Vegas, NV (ACCESSWIRE) -6.42%
Apr-21-23 08:30AM	Inhibikase Therapeutics to Present at the 2023 Planet MicroCap Showcase (PR Newswire)
Apr-07-23 10:25PM	Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-31-23 08:22AM	Inhibikase Therapeutics Reports Full Year 2022 Financial Results and Highlights Recent Period Activity (PR Newswire)
Mar-23-23 05:15PM	Inhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023 (PR Newswire) +8.66%
Mar-21-23 08:00AM	Inhibikase Therapeutics to Present at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (PR Newswire)
Mar-16-23 08:30AM	Inhibikase Therapeutics to Host Virtual R&D Event on March 22, 2023 (PR Newswire)
Mar-15-23 08:35AM	Inhibikase Therapeutics Provides Interim Update on the '501' Bioequivalence Study of IkT-001Pro (PR Newswire)
08:30AM	Loading…
Mar-08-23 08:30AM	Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Multiple System Atrophy (PR Newswire)
Feb-15-23 04:05PM	Inhibikase Therapeutics to Present at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit (PR Newswire) +7.81%
Feb-08-23 01:00PM	Inhibikase Therapeutics raises $10M as disease treatments show success (American City Business Journals) +5.25%
Jan-27-23 04:05PM	Inhibikase Therapeutics Announces Closing of $10 Million Concurrent Registered Direct Offering and Private Placement Priced At a Premium to Market Under Nasdaq Rules (PR Newswire) -7.32%
Jan-25-23 01:00PM	Inhibikase Therapeutics Announces $10 Million Concurrent Registered Direct Offering and Private Placement Priced at a Premium to Market Under Nasdaq Rules (PR Newswire) -5.49%
08:35AM	Inhibikase Therapeutics Announces Publication Demonstrating Potential for c-Abl as a Key Therapeutic Target in Parkinson's Disease and Related Disorders (PR Newswire)
08:05AM	Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Parkinson's Disease (PR Newswire)
Dec-12-22 04:05PM	Inhibikase Therapeutics Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro (PR Newswire) +5.80%
Dec-07-22 04:05PM	Inhibikase Therapeutics Provides Update to FDA Clinical Hold of IkT-148009 Programs (PR Newswire)
Nov-22-22 08:00AM	Inhibikase Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference (PR Newswire)
Nov-14-22 05:45PM	Inhibikase Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity (PR Newswire) +8.52%
Nov-10-22 05:00AM	The Petri Dish: Biogen's CEO search stalls again; A setback for Verve (American City Business Journals)
Nov-08-22 08:00AM	Inhibikase Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022 (PR Newswire) +5.49%
Nov-07-22 08:00AM	Inhibikase Therapeutics Announces FDA Clinical Hold on IkT-148009 Programs (PR Newswire) -40.91%
Oct-12-22 08:00AM	Inhibikase Therapeutics to Present at the Cambridge Healthtech Institute's Inaugural Neurodegeneration Targets Conference (PR Newswire)
Sep-21-22 04:05PM	Inhibikase Therapeutics to Present at the Grand Challenges in Parkinson's Disease Conference (PR Newswire)
Sep-15-22 08:00AM	Inhibikase Therapeutics to Present Data from Phase 1/1b study of IkT-148009 at the Movement Disorders Society Congress (PR Newswire) +12.11%
Sep-13-22 12:15PM	Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation (Simply Wall St.)
Sep-08-22 08:30AM	Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders (PR Newswire)
Sep-01-22 04:05PM	Inhibikase Therapeutics Appoints Gisele Dion to Board of Directors (PR Newswire)
Aug-26-22 08:00AM	Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia (PR Newswire) +9.51%
Aug-23-22 08:00AM	Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2a '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease (PR Newswire) +10.51%
Aug-12-22 04:55PM	Inhibikase Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity (PR Newswire)
Aug-08-22 08:30AM	Inhibikase Therapeutics to Report Second Quarter 2022 Financial Results on August 12, 2022 (PR Newswire) +13.58%
Jun-13-22 08:00AM	Inhibikase Therapeutics Announces Advancement of IkT-148009 Phase 2 '201' Program Following FDA Review (PR Newswire) -6.01%
May-16-22 05:00PM	Inhibikase Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity (PR Newswire)
May-10-22 08:05AM	Inhibikase Therapeutics to Participate at the H.C. Wainwright Global Investment Conference (PR Newswire) -11.10%
May-09-22 04:05PM	Inhibikase Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022 (PR Newswire) -10.48%
Apr-21-22 04:05PM	Inhibikase Therapeutics to Participate at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference (PR Newswire)
Apr-13-22 11:45AM	Vetoquinol: Q1 2022 Sales: 135M (Business Wire)
Apr-06-22 11:37AM	Is Inhibikase Therapeutics (NASDAQ:IKT) In A Good Position To Invest In Growth? (Simply Wall St.) +7.69%
08:00AM	Inhibikase Therapeutics to Host Virtual KOL Investor Event on April 20, 2022 (PR Newswire)
Mar-31-22 05:00PM	Inhibikase Therapeutics Reports Full Year 2021 Financial Results and Highlights Recent Period Activity (PR Newswire)
Mar-28-22 08:00AM	Inhibikase Therapeutics to Participate in the Next Generation Kinase Inhibitors Summit (PR Newswire)
Mar-25-22 08:00AM	Inhibikase Therapeutics to Report Full Year 2021 Financial Results on March 31, 2022 (PR Newswire)
Mar-23-22 08:00AM	Inhibikase Therapeutics to Participate in the Maxim Group 2022 Virtual Growth Conference (PR Newswire)
Mar-08-22 08:00AM	Inhibikase Therapeutics to Present Phase 1/1b Clinical Data at the Upcoming AD/PD Alzheimer's & Parkinson's Diseases Conference (PR Newswire) +12.62%
Jan-05-22 08:30AM	Inhibikase Therapeutics Highlights 2022 Pipeline Goals and Milestones (PR Newswire) -8.54%
Nov-29-21 08:05AM	Inhibikase Therapeutics Announces Publication Highlighting Mechanism of Disease and the Potential of Oral c-Abl Kinase Inhibitor Therapy for the Treatment of Parkinson's Disease (PR Newswire)
Nov-15-21 05:30PM	Inhibikase Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity (PR Newswire)
Oct-27-21 08:05AM	Inhibikase Therapeutics to Participate in Upcoming Michael J. Fox Foundation Alpha-Synuclein Summit (PR Newswire)
Oct-19-21 08:05AM	Inhibikase Therapeutics Announces Dosing of First Parkinson's Patient in its Phase 1b Clinical Trial of IkT-148009 (PR Newswire) +9.71%
Oct-04-21 09:57AM	Inhibikase Shares Interim 3-Month Toxicology Studies Data Of Parkinson's Candidate (Benzinga)
08:05AM	Inhibikase Therapeutics Announces Interim Three-month Results from Chronic Toxicology Studies of its Oral c-Abl Kinase Inhibitor, IkT-148009, in Development for Treatment of Parkinson's Disease (PR Newswire)
Sep-23-21 08:05AM	Inhibikase Therapeutics Receives Grant from U.S. National Institutes of Health to Evaluate IkT-148009 for the Treatment of Multiple System Atrophy (PR Newswire)
Sep-07-21 08:00AM	Inhibikase Therapeutics to Present at Upcoming H.C. Wainwright 23rd Annual Global Investment Conference (PR Newswire)
Aug-16-21 04:45PM	Inhibikase Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity (PR Newswire) -6.28%
Jul-26-21 10:09AM	Inhibikase To Start Testing Its Parkinson's Candidate In Patients (Benzinga)
08:42AM	Inhibikase Therapeutics Receives FDA Clearance To Begin Evaluation of IkT-148009 in Parkinson's Patients (PR Newswire)
Jun-18-21 06:45PM	Inhibikase Therapeutics Announces Closing of Follow-On Offering of Common Stock (PR Newswire)
Jun-16-21 08:00AM	Wednesdays Pre-Market: Heres What You Need to Know Before the Market Opens (TipRanks) -27.14%
06:57AM	Inhibikase Therapeutics Stock Drops After Follow-On Equity Offering Of $45M Issued At 26% Discount (Benzinga)
Jun-15-21 07:40PM	Inhibikase Therapeutics Prices Follow-On Public Offering of Common Stock (PR Newswire) -16.98%
May-25-21 08:00AM	Inhibikase Therapeutics to Present at Upcoming Jefferies Virtual Healthcare Conference & Others (PR Newswire) -6.66%
May-17-21 04:05PM	Inhibikase Therapeutics Reports First Quarter 2021 Financial Results and Highlights Recent Period Activity (PR Newswire)
Apr-21-21 08:00AM	Inhibikase Therapeutics to Present at Sachs 4th Annual Neuroscience Innovation Forum (PR Newswire)
Apr-01-21 08:00AM	Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity (PR Newswire)
Mar-02-21 08:05AM	Inhibikase Therapeutics to Present at H.C. Wainwright & Co. Global Life Sciences Virtual Conference (PR Newswire)
Feb-22-21 08:05AM	Inhibikase Therapeutics to Present at the American Society of Experimental Neurotherapeutics (ASENT) Conference (PR Newswire)
Feb-17-21 12:48PM	Inhibikase Initiates Early-Stage Study Of Parkinson's Candidate (Benzinga) +10.78%
08:05AM	Inhibikase Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial of IkT-148009 to Treat Parkinsons Disease and Related Disorders (Business Wire)
Jan-04-21 08:01AM	Inhibikase Therapeutics Announces Partnership with Clintrex Research Corporation; C. Warren Olanow, MD, to Serve as Interim Chief Medical Officer (PR Newswire)
Dec-28-20 10:33AM	Inhibikase Therapeutics Announces Closing of Initial Public Offering (PR Newswire)
Dec-23-20 05:12PM	Inhibikase, GBS Both Fall Below IPO Price in First Trading Day (Barrons.com)
Dec-22-20 06:25PM	Inhibikase Therapeutics, Inc. Announces Pricing of its Initial Public Offering (PR Newswire)

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in developing protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Atlanta, GA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IKT | Inhibikase Therapeutics Inc

Upgrade your FINVIZ experience